Amphastar Pharmaceuticals (AMPH) Raw Materials (2015 - 2026)

Amphastar Pharmaceuticals' Raw Materials history runs 12 years deep, the most recent figure standing at $104.7 million for Q1 2026.

• On a quarterly basis, Raw Materials rose 1.37% year-over-year to $104.7 million in Q1 2026; TTM through Mar 2026 was $104.7 million, a 1.37% increase from a year earlier, with the FY2025 full-year figure at $106.8 million, up 31.06% from the prior year.
• Raw Materials slipped to $104.7 million in Q1 2026 per AMPH's latest filing, from $106.8 million in the prior quarter.
• Across five years, Raw Materials topped out at $106.8 million in Q4 2025 and bottomed at $40.4 million in Q1 2022.
• The 5-year median for Raw Materials is $55.2 million (2023), against an average of $67.9 million.
• Across the five-year window, Raw Materials slipped 6.7% in 2022 and jumped 100.84% in 2025, its largest moves.
• Year by year, Raw Materials stood at $47.6 million in 2022, then grew by 5.2% to $50.1 million in 2023, then jumped by 62.76% to $81.5 million in 2024, then surged by 31.06% to $106.8 million in 2025, then slipped by 2.03% to $104.7 million in 2026.
• Per Business Quant, the three latest AMPH Raw Materials figures stand at $104.7 million (Q1 2026), $106.8 million (Q4 2025), and $105.8 million (Q3 2025).